This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for Mar 7, 2023
by Zacks Equity Research
Companies in The News Are: CIEN,BBIO,BA,SNAP
Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 67.4% upside potential for BridgeBio Pharma (BBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BridgeBio Pharma (BBIO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 11.96% and 146.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
BridgeBio Pharma (BBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
by Zacks Equity Research
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BridgeBio Pharma (BBIO) closed at $8.66, marking a -1.25% move from the previous day.
BridgeBio Pharma (BBIO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) closed at $10.02 in the latest trading session, marking a +0.1% move from the prior day.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.
BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) closed the most recent trading day at $8.54, moving -1.61% from the previous trading session.
BridgeBio Pharma (BBIO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) closed the most recent trading day at $9.99, moving +1.83% from the previous trading session.
BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.
BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
by Zacks Equity Research
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.
BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study
by Zacks Equity Research
BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.
BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) closed the most recent trading day at $14.65, moving -1.81% from the previous trading session.